Gold prices near 3-week lows as stronger dollar, trade progress weigh
EMERYVILLE, Calif. – Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing vaccines with a market capitalization of $1.38 billion, has reached out to its shareholders ahead of the upcoming Annual Meeting on June 11, 2025. The company is advocating for the re-election of its four current director nominees, emphasizing their contributions to the company’s recent success and future prospects.
The board of Dynavax, recently refreshed with industry experts, has overseen significant achievements, including a 267% total shareholder return over the past five years and the successful commercialization of its hepatitis B vaccine, HEPLISAV-B®. The vaccine attained a record $268 million in net product revenue in 2024, capturing approximately 44% of the U.S. total market share. According to InvestingPro data, the company maintains impressive revenue growth of 19.36% and a healthy gross margin of nearly 61%. InvestingPro analysis indicates the stock is currently trading slightly below its Fair Value.
Dynavax’s board has also been instrumental in advancing the company’s pipeline, including a shingles vaccine with Phase 1/2 trial results expected in Q3 2025 and the initiation of a Phase 2 trial for a plague vaccine in the same quarter. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 10.8, providing ample resources for its development programs. For deeper insights into Dynavax’s financial position and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro. The latter is part of a multi-year partnership with the U.S. Department of Defense.
The company is executing a $200 million share repurchase program, with $128.8 million already completed as of the end of Q1 2025. Furthermore, Dynavax recently refinanced a majority of its outstanding Convertible Senior Notes, which is expected to strengthen its capital structure.
The directors up for re-election are Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun, each bringing a wealth of experience across the biotechnology and vaccine industry. The board’s statement suggests that the nominees’ expertise is crucial for guiding Dynavax through a pivotal year and contrasts their qualifications with those of the nominees proposed by Deep Track Capital, which the company claims lack comparable experience.
Dynavax warns that Deep Track Capital’s plan, which includes an accelerated share repurchase program and a shift in focus solely to HEPLISAV-B® commercialization, could undermine the long-term value of the company.
This news article is based on a press release statement from Dynavax Technologies Corporation.
In other recent news, Dynavax Technologies Corporation has reported its fiscal year 2024 earnings, revealing a diluted earnings per share (EPS) of $0.05, which surpassed expectations. However, the company fell short on revenue forecasts, reporting $71.1 million against an anticipated $72.44 million. Dynavax’s HEPLISAV-B vaccine achieved a significant market share in the U.S. adult Hepatitis B market, contributing to a total of $268 million in revenues for the year. Looking forward, the company projects HEPLISAV-B net product revenue between $305 million and $325 million for 2025. Analyst Edward White of H.C. Wainwright maintained a Buy rating for Dynavax with a $31 price target, while JMP Securities’ Roy Buchanan raised the price target to $33, maintaining a Market Perform rating. Additionally, Dynavax executed a $100 million accelerated share repurchase transaction as part of its $200 million share repurchase program. Meanwhile, Recursion announced the appointment of Namandjé Bumpus, Ph.D., and Elaine Sun to its Board of Directors, aiming to bolster its strategic leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.